Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: A questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology

International Journal of Hematology

Volumn 84, Issue 5, 2006, Pages 406-412

  Gotoh, Akihiko ^a   Ohyashiki, Kazuma ^a,b   Oshimi, Kazuo ^a   Usui, Noriko ^a   Hotta, Tomomitsu ^a   Dan, Kazuo ^a   Ikeda, Yasuo ^a  

^a Japanese Society of Hematology   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bortezomib; Corticosteroid; Lung injury; Stem cell transplantation

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; INTERFERON; PREDNISOLONE; STEROID; THALIDOMIDE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FATALITY; FATIGUE; FISHER EXACT TEST; GASTROINTESTINAL SYMPTOM; HEMATOLOGY; HUMAN; INCIDENCE; JAPAN; LUNG INJURY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEUROTOXICITY; QUESTIONNAIRE; RESPIRATORY FAILURE; RISK FACTOR; RISK REDUCTION; STEM CELL TRANSPLANTATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BORONIC ACIDS; DRUG APPROVAL; FEMALE; HEMATOLOGY; HUMANS; JAPAN; LUNG; LUNG DISEASES; MALE; MULTIPLE MYELOMA; PYRAZINES; QUESTIONNAIRES; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION;

EID: 33846029822     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06142     Document Type: Article

References (17)

1. Bross PF, Kane R, Farrell AT, et al. Approval summary tor bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954-3964.
2. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783.
3. Richardson PG, Barlogic B, Berenson J, et al. A phase 2 study of hortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
4. Jagannath S, Barlogic B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
5. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492-3494.
6. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
7. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28:103-113.
8. Inokuma S, Sakata M, Yoshida A, Shiratori K, Kiyosawa H. Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol. 1996;23:1282-1285.
9. Kamata Y, Anara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201-1204.
10. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22:561-573.
11. Verleden GM, du Bois RM, Bouros D, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J. 2001;32(suppl):17s-29s.
12. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005;45:465-476.
13. Everhart MB, Han W, Sherrill TP, et al. Duration and intensity of NF-κB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006;176:4995-5005.
14. Tian XF, Yao JH, Li YH, et al. Effect of nuclear factor kappa B on intercellular adhesion molecule-1 expression and neutrophil infiltration in lung injury induced by intestinal ischemia/reperfusion in rats. World J Gastroenterol. 2006;12:388-392.
15. Yang G, Abate A, George AG, Weng YH, Dennery PA. Maturational differences in lung NF-κB activation and their role in tolerance to hyperoxia. J Clin Invest. 2004;114:669-678.
16. Franek WR, Morrow DM, Zhu H, et al. NF-κB protects lung epithelium against hyperoxia-induced nonapoptotic cell death-oncosis. Free Radic Biol Med. 2004;37:1670-1679.
17. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-762.